RANCHO SANTA FE, Calif.--(BUSINESS WIRE)--NuSight Medical, an emerging ophthalmic care company, has introduced The NuLids System. This novel, safe and effective, doctor prescribed, home-use medical device that efficiently treats dry eye was introduced at the American Optometric Association meeting in Denver, CO, June 20-24, 2018. By gently stimulating, de-capping, and rejuvenating the Meibomian glands to a healthier state, NuLids improves dry eye clinical signs and symptoms.
“NuLids is a win-win for treating dry eye” said Rob Foster, President & CEO, NuSight Medical. “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice. And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”
“About 86% of dry eye patients have compromised Meibomian gland function which results in an unstable tear film and subsequent premature breakdown of the tear,” said John Olkowski, MD, Founder and Chairman of NuSight Medical. “The oil produced by the Meibomian glands forms an effective barrier to tear evaporation. With NuLids aiding the production and flow of meibum, the clinical signs and symptoms of dry eye are significantly reduced.”
In a recent multi-center clinical study, the NuLids System demonstrated a 65% improvement in Tear Breakup Time and an 81% improvement in Meibomian Glands Yielding Liquid Secretions. The vast majority of patients reported a two-fold improvement in their dry eye symptoms after only two weeks of daily use.
NuLids can be complementary with in-office procedures performed by eye doctors. Patients like the NuLids System because it is safe, effective, and easy to use without any known side effects. They also appreciate that it is cost effective and may reduce the need for expensive OTC lubricants and/or co-payments for pharmaceuticals.
NuLids takes only 60 seconds per day to use and patients quickly adapt to the simple routine. The NuLids I and NuLids II clinical studies found that 95% of patients surveyed after the 30 day trial reported being either “satisfied” or “very satisfied” with the overall treatment.”
Dry eye is known to affect more than 33% of Americans. It is a major reason for visits to the eye doctor. Dry eye is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. The effects of dry eye include irritation, inflammation, and even possible scarring on the surface of the eye. Dry eye is a major medical market in the US -- $4.0 billion and growing at 12% per year.
The NuSight Medical team is pleased to introduce such a valuable tool in the fight against dry eye. We look forward to introducing additional doctor-prescribed, home-use products that provide real relief to patients with dry eye disease in the near future.
NuLids will be featured at Booth # 603 at AOA. For more information visit: www.NuSightMedical.com, or call 1 833.3NULIDS [1-833-368-5437].